Nano-ART and NeuroAIDS.

Area of Science:

• Neuroscience
• Pharmacology
• Nanotechnology

Background:

• Human Immunodeficiency Virus (HIV) readily infects the central nervous system (CNS), establishing a viral reservoir.
• Highly Active Antiretroviral Therapy (HAART) has improved outcomes for AIDS patients, but CNS penetration of drugs remains a challenge.
• The blood-brain barrier (BBB) restricts the entry of antiretroviral (ARV) drugs into the CNS due to its structure, efflux pumps, and metabolic enzymes.

Purpose of the Study:

• To explore the potential of nanotechnology to enhance the delivery of ARV drugs across the BBB.
• To review how nanoformulations can overcome barriers to CNS drug entry for improved NeuroAIDS treatment.
• To discuss the impact of improved CNS drug delivery on pharmacokinetics, biodistribution, and clinical outcomes.

Main Methods:

• Review of existing literature on nanotechnology applications in drug delivery for CNS disorders.
• Analysis of how nanoformulation properties (size, shape, coatings) can facilitate BBB crossing.
• Examination of strategies to overcome BBB efflux pumps and metabolic enzymes using nano-based approaches.

Main Results:

• Nanoformulations can be engineered to circumvent the BBB, improving drug delivery to the CNS.
• Nanotechnology offers methods to modulate efflux pumps and enzymes that hinder ARV drug entry.
• Optimized nano-delivery systems can enhance drug uptake, controlled release, and penetration across the BBB.

Conclusions:

• Nanotechnology presents a viable strategy to improve antiretroviral therapy for the CNS, termed NanoART.
• Enhanced drug delivery across the BBB via nanotechnology can significantly impact the biodistribution and clinical effectiveness for NeuroAIDS.
• Developing targeted and controllable nano-delivery systems is crucial for the global effort to manage and eliminate HIV progression in the CNS.